A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh HK, Jackson C, Shiraz P, Jeyakumar N, Hamilton MP, Egeler E, Mavroukakis S, Kuo A, Cancilla J, Sahaf B, Agarwal N, Kanegai AM, Kramer AM, Arai S, Bharadwaj S, Dahiya S, Hosoya H, Johnston LJ, Kennedy VE, Liedtke M, Lowsky R, Mikkilineni L, Negrin RS, Rezvani AR, Sidana S, Shizuru JA, Smith M, Weng WK, Feldman SA, Frank MJ, Lee Z, Tagliaferri M, Marcondes AMQ, Miklos DB, Mackall CL, Muffly L.
Srinagesh HK, et al. Among authors: sidana s.
Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952. Online ahead of print.
Blood. 2024.
PMID: 38968138